Results 111 to 120 of about 90,766 (269)

Clinical Scalar Electrocardiography [PDF]

open access: green, 1965
Sanford A. Franzblau
openalex   +1 more source

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF

open access: yesEuropean Journal of Heart Failure, EarlyView.
Effect of finerenone on a hierarchical endpoint. CI, confidence interval; CV, cardiovascular; EF, ejection fraction; HF, heart failure. ABSTRACT Aims FINEARTS‐HF demonstrated the efficacy of finerenone in reducing total worsening heart failure (HF) events (first and recurrent) and cardiovascular death, compared to placebo, in patients with HF and ...
Toru Kondo   +23 more
wiley   +1 more source

Takotsubo cardiomyopathy during armed conflict: A case series

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha   +13 more
wiley   +1 more source

Longest survivor of pulmonary atresia with ventricular septal defect without surgical intervention

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1499-1507, April 2025.
Sang Zhou   +5 more
wiley   +1 more source

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang   +3 more
wiley   +1 more source

Research progress on the use of the optical coherence tomography system for the diagnosis and treatment of central nervous system tumors

open access: yesIbrain, Volume 11, Issue 1, Page 3-18, Spring 2025.
With the advantages of high‐resolution imaging, efficient image acquisition, intraoperative real‐time detection, and radiation‐free and noninvasive characteristics, optical coherence tomography (OCT) provides accurate diagnosis and effective intraoperative guidance for the minimally invasive diagnosis and treatment of central nervous system (CNS ...
Jiuhong Li   +10 more
wiley   +1 more source

Hematologic and molecular responses to ropeginterferon alfa‐2b therapy of polycythemia vera: 48‐week results from a prospective study

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Current treatment goals for polycythemia vera, a myeloproliferative neoplasm characterized by JAK2 mutations, are mainly to prevent thrombosis. While ropeginterferon alfa‐2b treatment also reduces JAK2 mutation burden, the correlation between the hematologic and molecular responses remains to be clarified.
Seug Yun Yoon   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy